Kailera Therapeutics, Inc. - Common stock (KLRA)

25.54
+1.28 (5.28%)
NASDAQ · Last Trade: May 6th, 11:14 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
A Kailera Therapeutics (KLRA) Insider Scooped up an Additional 500,000 Shares for $8.0 Millionfool.com
Kailera Therapeutics, a clinical-stage biotech focused on obesity treatments, just reported a notable insider buy in recent SEC filings.
Via The Motley Fool · April 27, 2026